EyePoint, Inc. (EYPT)

3.14 +0.13 (+4.32%) USD  |  NASDAQ  |  Oct 15, 16:00
3.155 +0.02 (+0.48%) After-Hours: 20:00
More

EyePoint Cash from Operations (TTM) : -267.30M for June 30, 2026

Cash from Operations (TTM) Chart

Historical Cash from Operations (TTM) Data

View and export this data back to 2008. Start Trial.
Date Value
June 30, 2026 -267.30M
March 31, 2026 -267.54M
December 31, 2025 -240.11M
September 30, 2025 -210.91M
June 30, 2025 -190.59M
March 31, 2025 -148.18M
December 31, 2024 -126.23M
September 30, 2024 -113.49M
June 30, 2024 -89.66M
March 31, 2024 -12.46M
December 31, 2023 1.875M
September 30, 2023 12.40M
June 30, 2023 14.46M
March 31, 2023 -61.68M
December 31, 2022 -65.00M
September 30, 2022 -69.08M
June 30, 2022 -63.74M
March 31, 2022 -55.16M
December 31, 2021 -50.10M
September 30, 2021 -27.53M
June 30, 2021 -18.61M
March 31, 2021 -13.19M
December 31, 2020 -14.44M
September 30, 2020 -31.82M
June 30, 2020 -47.72M
Date Value
March 31, 2020 -59.71M
December 31, 2019 -56.70M
September 30, 2019
June 30, 2019
March 31, 2019
December 31, 2018
September 30, 2018
June 30, 2018
March 31, 2018
June 30, 2017 -20.49M
March 31, 2017 -20.38M
December 31, 2016 -20.14M
September 30, 2016 -18.31M
June 30, 2016 -16.32M
March 31, 2016 -14.98M
December 31, 2015 -14.63M
September 30, 2015 9.798M
June 30, 2015 10.30M
March 31, 2015 10.52M
December 31, 2014 12.62M
September 30, 2014 -10.89M
June 30, 2014 -10.67M
March 31, 2014 -11.27M
December 31, 2013 -11.38M
September 30, 2013 -10.90M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Ocular Therapeutix, Inc. -238.24M
Eli Lilly & Co. 28.08B
Nuvation Bio, Inc. -120.52M
ANI Pharmaceuticals, Inc. 189.47M
Corcept Therapeutics, Inc. 109.70M